ESC: Study Confirms Cutting Salt Intake Can Reduce Strokes and Heart Attacks
SSaSS trial finds mortality benefit for salt substitute vs salt Reducing the use of discretionary...
Read MoreSep 6, 2021
SSaSS trial finds mortality benefit for salt substitute vs salt Reducing the use of discretionary...
Read MoreSep 2, 2021
STEP results demonstrate clinical benefit when systolic drops below 130 mmHg An intensive blood...
Read MoreAug 25, 2021
Investigators used a Web-based recording system, as well as face-to-face regional benchmark analysis and educational meetings, in the BLITZ-HF prospective study to evaluate and improve adherence to heart failure (HF)...
Read MoreAug 25, 2021
With data lacking on acute coronary syndrome (ACS) in patients with heart failure (HF), researchers examined the characteristics and outcomes of non-ST elevation ACS (NSTACS) in patients with and without a prior medical history...
Read MoreAug 25, 2021
With sodium-glucose co-transporter 2 (SGLT-2) inhibitors becoming increasingly relevant for the treatment and prevention of heart failure (HF), study investigators sought to assess various SGLT-2 inhibitors in patients with...
Read MoreAug 25, 2021
To evaluate the cardiovascular (CV) benefits of sodium-glucose co-transporter 2 (SGLT-2) inhibitors according to 1) patient history of heart failure (HF) and 2) severity of left ventricular ejection fraction (LVEF) reduction in...
Read MoreAug 25, 2021
To examine outcomes in patients with chronic kidney disease, or CKD, with and without type 2 diabetes by history of HF at baseline, researchers assessed data on 4,304 patients—including 468 with a diagnosis of HF at...
Read MoreJul 16, 2021
A recently published phase 2 study in Lancet Oncology showed that the combination of neoadjuvant durvalumab with stereotactic body radiotherapy (SBRT) is safe and grants a nearly 55% major pathologic response rates among...
Read MoreJul 14, 2021
The DESTINY-Breast07 trial will test trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer, as a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion...
Read MoreJul 14, 2021
The phase 3 ELEVATE-RR trial was a head-to-head comparison of acalabrutinib versus ibrutinib in previously treated patients with chronic lymphocytic leukemia. The first results of this study demonstrated that acalabrutinib had...
Read MoreJul 14, 2021
Acalabrutinib with or without obinutuzumab demonstrated superior long-term efficacy over obinutuzumab + chlorambucil in patients with chronic lymphocytic leukaemia (CLL). Results from the 4-year follow-up of the ELEVATE-TN study...
Read MoreJul 14, 2021
The addition of durvalumab after chemoradiation (CRT) in unresectable stage 3 non-small cell lung cancer (NSCLC) can be safely delivered in elderly patients ≥70 years with comparable improvement in overall survival (OS), as...
Read MoreJul 14, 2021
Median overall survival doubled for veterans with stage 3 non-small cell lung cancer who received chemoradiotherapy plus durvalumab, as compared to those receiving chemoradiotherapy alone, according to a new study presented at...
Read MoreJul 14, 2021
Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has durable...
Read MoreJul 8, 2021
Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has just as durable...
Read MoreJul 8, 2021
Updated findings of the PACIFIC trial showed an overall survival (OS) rate of 43% after 5 years of treatment with durvalumab, which has . Physician’s Weekly spoke with Dr. Camille Hertzka, vice president and head of Oncology, US...
Read MoreJul 8, 2021
Adavosertib with or without olaparib demonstrated clinical activity with a manageable toxicity...
Read MoreJul 1, 2021
For a presentation at ASCO 2021, John Seymour, PhD, Professor at the Peter MacCallum Cancer Centre of the Royal Melbourne Hospital and University of Melbourne in Australia, discussed six FDA-approved agents or drug...
Read MoreJul 1, 2021
For a review presented at ASCO 2021, Sonali M. Smith, MD, FASCO, Elwood V. Jensen Professor in Medicine and Chief of the Section of Hematology/Oncology at the University of Chicago, discussed the findings of two studies focused...
Read MoreJul 1, 2021
TG-1701 (TG Therapeutics) is an investigational, once-daily, selective, convalent, oral Bruton tyrosine kinase inhibitor. Prior research has shown that inhibition of Bruton tyrosine kinase is superior to standard...
Read More